A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients with glioblastoma at first progression

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501822-39-00

Acronym

PH-L19TNFCCNU-02-20

Enrollment

113

Registered

2023-02-15

Start date

2023-07-31

Completion date

Unknown

Last updated

2025-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Germany, Italy

None listed

Source: EU CTIS · Data processed: Feb 4, 2026